Alexion reports revenue up, profit down on restructuring costs

ALEXION PHARMACEUTICALS reported a 17 percent decline in profit for the 2017 third quarter as the company's expenses rose on restructuring and its cost of sales. Above, the Alexion manufacturing facility in Smithfield, which the company remains committed to closing as part of its corporate restructuring. / COURTESY ALEXION
ALEXION PHARMACEUTICALS reported a 17 percent decline in profit for the 2017 third quarter as the company's expenses rose on restructuring and its cost of sales. Above, the Alexion manufacturing facility in Smithfield, which the company remains committed to closing as part of its corporate restructuring. / COURTESY ALEXION
SMITHFIELD – New Haven, Conn.-based Alexion Pharmaceuticals Inc. reported a 17 percent year-over-year decline in net income for the 2017 third quarter to $78 million, or 35 cents per diluted share, which fell 7 cents over the year. The biopharmaceutical company that focuses on drugs for rare diseases increased third-quarter revenue by 7.5 percent year…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -